Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.
 

 
By Jeffrey Bouley, DDNews Chief Editor
Multiple Myeloma Research Foundation announces six new clinical trials in 2014, and Cellectar Biosciences announces IND for relapsed or refractory multiple myeloma drug
 
By Lloyd Dunlap, DDNews Managing Editor
With some tinkering, MIT chemists recruit anthrax to deliver anti-cancer drugs
 
Guest Commentary: Developing humanized cancer models for cost-effective and productive cancer drug discovery
By Dr. Jean-Pierre Wery, CrownBio
Oncology drug discovery faces one of the highest attrition rates for drug candidates in the development pipeline, largely due to efficacy issues. More relevant clinical models, ones that better reflect cancer heterogeneity and disease progression, could address this problem.
 
By Lloyd Dunlap, DDNews Managing Editor
FDA submission reinforces commitment to addressing significant unmet needs for patients with acute lymphoblastic leukemia, an aggressive cancer with limited treatment options
 
DDNews Cancer Research Exclusive: Turning an eye to TERT
By Kelsey Kaustinen, DDNews Senior Editor
As part of the TCGA initiative, researchers have discovered multiple cases of missing chromosomes in chromophobe renal cell carcinoma, as well as rearrangements in the promoter region of the TERT gene
 
 
 
 
 
Agios, iNovacia announce new collaboration
March 2012
SHARING OPTIONS:

STOCKHOLM, Sweden—iNovacia AB has announced a high-throughput screening collaboration with Cambridge, Mass.-based Agios Pharmaceuticals, a company focusing on cancer metabolism. Per the terms of the agreement, iNovacia will provide small-molecule lead generation services for the collaboration in addition to identifying modulators of pharmaceutical targets of interest to Agios through use of iNovacia's proprietary screening library. Financial details for the collaboration were not disclosed.
 
"We have had successful screening projects with Agios in the past and we are now proud to be able to extend this relationship," Dr. Thomas Olin, CEO of iNovacia, said in a press release. "We are pleased that Agios and other U.S. and European companies continue to appreciate the value of our premium screening operations and proprietary screening library as a means to generate high-quality chemistry starting points."

Back







CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.